Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Dr Katherine Pumphrey joins Ethics Talk to discuss her article, coauthored with Dr Jessica Hart: “What the COVID-19 Pandemic Teaches Us About Pediatric Iatrogenic Risk.”
Trauma-informed care ensures ethical treatment for children experiencing physical or psychological distress associated with a medical event or procedure.
AMA J Ethics. 2017;19(8):793-801. doi:
10.1001/journalofethics.2017.19.8.pfor1-1708.
Dr Amy B. Cadwallader joins Ethics Talk to discuss her article, coauthored with Kavitha Nallathambi: “How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?”